MedTrace Logo

Reducing Mortality in Adults With Advanced HIV Disease (REVIVE)

NCT05580666 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 8000

Last updated 2025-09-03

No results posted yet for this study

Summary

A double blinded, placebo-controlled, multicenter trial to evaluate effectiveness of azithromycin prophylaxis on mortality in advanced HIV.

Conditions

  • HIV Disease Progression

Interventions

DRUG

Azithromycin Oral Tablet

Antimicrobial therapy

DRUG

Placebo oral tablet

Inert ingredients

Sponsors & Collaborators

  • Population Health Research Institute

    lead OTHER

Principal Investigators

  • John Eikelboom, MBBS, MSc, FRCPC · Population Health Research Institute

  • Sean Wasserman, MBChB, PhD · University of Cape Town

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-08
Primary Completion
2028-11-30
Completion
2029-05-31

Countries

  • Côte d’Ivoire
  • Ethiopia
  • Ghana
  • Malawi
  • Mozambique
  • Nigeria
  • Rwanda
  • Sierra Leone
  • South Africa
  • Uganda
  • Zambia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05580666 on ClinicalTrials.gov